Lunit's AI boosts Guardant Health's cancer detection capability

The Lunit SCOPE PD-L1 does AI-based quantification of tissue samples using a scoring system. Integrating it with the Guardant test will enhance biomarker assessment for NSCLC patients, the company claimed in a press statement. The AI has helped lift the test's detection of PD-L1 by over 20% compared to manual pathologist interpretation.